Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1313-1322

  Lutz, Amelie M ^a   Bachawal, Sunitha V ^a   Drescher, Charles W ^b   Pysz, Marybeth A ^a   Willmann, Jurgen K ^a   Gambhir, Sanjiv Sam ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD276; CONTRAST MEDIUM; FLUOROCARBON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER TISSUE; CAPILLARY DENSITY; CARCINOGENESIS; CELL ADHESION; CELL ENGINEERING; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC KIT; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VIVO STUDY; MICROBUBBLE; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR IMAGING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS REGULATION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ULTRASOUND MOLECULAR IMAGING;

ANIMALS; B7 ANTIGENS; CELL LINE, TUMOR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HETEROGRAFTS; HUMANS; MICE; MICROBUBBLES; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; OVARIAN NEOPLASMS;

EID: 84895826704     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1642     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin 2012;62:10-29.
2. Del Carmen MG. Primary epithelial ovarian cancer: diagnosis and management. Am Soc Clin Oncol Educ Book 2006;330-334.
3. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521-8.
4. van Nagell JR Jr., DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 2007;109: 1887-96.
5. Lutz AM, Willmann JK, Drescher CW, Ray P, Cochran FV, Urban N, et al. Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology 2011;259:329-45.
6. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295-303.
7. Willmann JK, Lutz AM, Paulmurugan R, Patel MR, Chu P, Rosenberg J, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008;248:936-44.
8. Willmann JK, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M, Lutz AM, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008;246:508-18.
9. Bzyl J, Lederle W, Rix A, Grouls C, Tardy I, Pochon S, et al. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38). Eur Radiol 2011;21:1988-95.
10. Lee DJ, Lyshchik A, Huamani J, Hallahan DE, Fleischer AC. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med 2008;27:855-66.
11. Deshpande N, Ren Y, Foygel K, Rosenberg J, Willmann JK. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. Radiology 2011;258:804-11.
12. Bzyl J, Palmowski M, Rix A, Arns S, Hyvelin JM, Pochon S, et al. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55). Euro Radiol 2013;23:468-75.
13. Sugino N, Kashida S, Takiguchi S, Karube A, Kato H. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. J Clin Endocrinol Metab 2000;85:3919-24.
14. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J,HammondR, Katsaros D, et al. Tumor vascular proteins as biomarkers in ovarian cancer. J. Clin Oncol 2007;25:852-61.
15. Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, KatsarosD, et al. Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther 2011;12:169-80.
16. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern Pathol 2010;23:1104-12.
17. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007;11:539-54.
18. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008;14: 5150-7.
19. Brunner A, Hinterholzer S, Riss P, Heinze G, Brustmann H. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol Oncol 2012;124:105-11.
20. Laib AM, Bartol A, Alajati A, Korff T, Weber H, Augustin HG. Spheroidbased human endothelial cell microvessel formation in vivo. Nat Protocols 2009;4:1202-15.
21. Lipofectamine 2000 Reagent Manual [cited 2014 Jan 2]. Available from: http://tools.lifetechnologies.com/content/sfs/manuals/Lipofectamine-2000-Reag- protocol.pdf.
22. Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M, Willmann JK. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010;256: 519-27.
23. Weidner N. Chapter 14: Measuring intratumoral microvessel density. Methods Enzymol 2008;444:305-23.
24. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004;10:1032-42.
25. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997;94:861-6.
26. Weller GE, Wong MK, Modzelewski RA, Lu E, Klibanov AL, Wagner WR, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res 2005;65:533-9.
27. Willmann JK, Cheng Z, Davis C, Lutz AM, Schipper ML, Nielsen CH, et al. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008;249:212-9.
28. Kaufmann BA, Carr CL, Belcik JT, Xie A, Yue Q, Chadderdon S, et al. Molecular imaging of the initial inflammatory response in atherosclerosis: implications for early detection of disease. Arterioscler Thromb Vasc Biol 2010;30:54-9.
29. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994;86:614-9.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDC(T)) method. Methods 2001;25:402-8.
31. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther 2006;5:2435-43.
32. Klibanov AL, Rasche PT, Hughes MS, Wojdyla JK, Galen KP, Wible JHJr., et al. Detection of individual microbubbles of an ultrasound contrast agent: fundamental and pulse inversion imaging. Acad Radiol 2002;S279-81.
33. Augustin HG. Vascular morphogenesis in the ovary. Bailliere's Best Prac Res Clin Obstet Gynaecol 2000;14:867-82.
34. Urban N, McIntosh MW, Andersen M, Karlan BY. Ovarian cancer screening. Hematol Oncol Clin North Am 2003;17:989-1005, ix.
35. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discovery 2008;7:591-607.
36. Alajati A, Laib AM, Weber H, Boos AM, Bartol A, Ikenberg K, et al. Spheroid-based engineering of a human vasculature in mice. Nat Methods 2008;5:439-45.